Published in final edited form as:

Thromb Haemost. 2008 January ; 99(1): 240. doi:10.1160/TH07-08-0520.

B-2 adrenergic receptor and venous thromboembolism [Letter to the Editor]

Aaron R. Folsom, MD, James M. Peacock, PhD, Eric Boerwinkle, PhD, and Mary Cushman, MD, MSc

Dear Editor:

Zee et al recently reported a nested case-control study of 92 gene polymorphisms in relation to venous thromboembolism (VTE) incidence (1). They discovered a statistically significant association of idiopathic, but not total, VTE with the Q27E β_2 -adrenergic receptor (β_2 -AR) polymorphism (gln27glu substitution). Odds ratios for genotypes containing the variant allele were modest, ranging from 1.4–1.8 depending on the model (additive, dominant, or recessive). In contrast, Nossent et al found no association between the Q27E polymorphism and VTE in the Leiden Thrombophilia Study (2), and O'Donnell et al found no association in a small case-control study (3). Because we had measured this Q27E polymorphism in the large Atherosclerosis Risk in Communities (ARIC) Study cohort (4), we sought to replicate the finding by Zee et al. We also examined another β_2 -AR polymorphism (gly16arg) that Zee et al, Nossent et al, and O'Donnell et al found unassociated with VTE (1–3).

The ARIC cohort was recruited in 1987–89 from four US communities, underwent epidemiologic examinations, and was followed for cardiovascular events (4). Among 14,210 ARIC participants at risk, 278 VTEs ($n = 111$ idiopathic) were verified between 1987 and 2002. Like Zee et al, we found no association of the gly16arg polymorphism with VTE. We also found a modest positive but statistically nonsignificant association between the Q27E polymorphism and both total and idiopathic VTE occurrence in ARIC (Table).

Further adjustment for body mass index and diabetes, two other risk factors for VTE in ARIC, did not change this finding.

In conclusion, the Q27E β_2 -AR polymorphism was not related to VTE in ARIC, unlike the study by Zee et al (1). It is possible that there is a modest association that we had insufficient power to detect, so a meta-analysis of existing studies could be helpful.

Sincerely,

References

1. Zee RYL, Cook NR, Cheng S, et al. Polymorphism in the β_2 -adrenergic receptor and lipoprotein lipase genes as risk determinants for idiopathic venous thromboembolism: A multilocus, population-based, prospective genetic analysis. *Circulation* 2006;113:2193–2200. [PubMed: 16651467]
2. Nossent AY, Dai L, Rosendaal FR, et al. Beta 2 adrenergic receptor polymorphisms: association with factor VIII and von Willebrand factor levels and the risk of venous thrombosis. *J Thromb Haemost* 2005;3:405–407. [PubMed: 15670061]
3. O'Donnell J, Manning RA, Laffan MA. Beta-adrenergic receptor polymorphisms in patients with elevated factor VIII levels with venous thrombosis. *Br J Haematol* 2003;123:139–141. [PubMed: 14510956]
4. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. *Am J Epidemiol* 1989;129:687–702. [PubMed: 2646917]

TABLE
Hazard Ratio (HR) for β_2 -AR Q27E (gln27 glu) Polymorphism and Venous Thromboembolism (VTE) in ARIC

Endpoint	Minor allele (G) Frequency	Model	Age, sex, and race-adjusted		
			HR	95% CI	
All VTE	0.37	Additive	1.00	Ref	
		CG	1.01	(0.77, 1.32)	
		GG	1.34	(0.94, 1.90)	
Idiopathic VTE		Dominant	1.08	(0.84, 1.39)	
		Recessive	1.33	(0.97, 1.83)	
		Additive	1.00	Ref	
		CG	0.93	(0.60, 1.43)	
		GG	1.41	(0.81, 2.43)	
		Dominant	1.03	(0.69, 1.54)	
		Recessive	1.47	(0.90, 2.40)	